- Home
- FND vs INAB Comparison
FND vs INAB Comparison
Compare FND & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FND
- INAB
- Stock Information
- Founded
- FND 2000
- INAB 2016
- Country
- FND United States
- INAB United States
- Employees
- FND N/A
- INAB N/A
- Industry
- FND RETAIL: Building Materials
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- FND Consumer Discretionary
- INAB Health Care
- Exchange
- FND Nasdaq
- INAB Nasdaq
- Market Cap
- FND 10.9B
- INAB 24.0M
- IPO Year
- FND 2017
- INAB 2021
- Fundamental
- Price
- FND $101.53
- INAB $0.25
- Analyst Decision
- FND Hold
- INAB Strong Buy
- Analyst Count
- FND 19
- INAB 3
- Target Price
- FND $104.37
- INAB $7.75
- AVG Volume (30 Days)
- FND 1.5M
- INAB 748.9K
- Earning Date
- FND 10-30-2024
- INAB 11-12-2024
- Dividend Yield
- FND N/A
- INAB N/A
- EPS Growth
- FND N/A
- INAB N/A
- EPS
- FND 1.80
- INAB N/A
- Revenue
- FND $4,396,475,000.00
- INAB N/A
- Revenue This Year
- FND $1.27
- INAB N/A
- Revenue Next Year
- FND $9.71
- INAB N/A
- P/E Ratio
- FND $56.30
- INAB N/A
- Revenue Growth
- FND N/A
- INAB N/A
- 52 Week Low
- FND $89.06
- INAB $0.22
- 52 Week High
- FND $135.67
- INAB $1.93
- Technical
- Relative Strength Index (RSI)
- FND 36.10
- INAB 39.26
- Support Level
- FND $97.09
- INAB $0.28
- Resistance Level
- FND $110.76
- INAB $0.32
- Average True Range (ATR)
- FND 3.72
- INAB 0.03
- MACD
- FND -1.61
- INAB -0.01
- Stochastic Oscillator
- FND 8.63
- INAB 13.73
About FND Floor & Decor Holdings Inc.
Floor & Decor Holdings Inc operates as a specialty retailer in the hard surface flooring market. Its stores offer a range of tile, wood, laminate, and natural stone flooring products, as well as decorative and installation accessories at everyday low prices. It appeals to a variety of customers including professional installers, commercial businesses, Do It Yourself (DIY) customers, and customers who buy the products for professional installation. Geographically, the group has a presence in the United States region and also offers its product through an e-commerce site.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.